Aditxt Subsidiary Ignite Proteomics Appoints Jeff Busch as CEO

Thursday, Mar 19, 2026 8:18 am ET1min read
ADTX--

Aditxt subsidiary Ignite Proteomics has appointed Jeff Busch as CEO, bringing public company leadership and capital markets experience to the precision oncology platform. Busch will lead commercial expansion and evaluate strategic growth and financing alternatives. The platform guides cancer therapy selection through functional protein profiling and has Medicare reimbursement, growing clinical validation, and a large addressable market. Busch's focus is on disciplined execution and creating durable public market equity value.

Aditxt Subsidiary Ignite Proteomics Appoints Jeff Busch as CEO

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet